<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302430</url>
  </required_header>
  <id_info>
    <org_study_id>14-15259</org_study_id>
    <nct_id>NCT02302430</nct_id>
  </id_info>
  <brief_title>Intranasal Oxytocin and Enhancement of Team Cohesion</brief_title>
  <acronym>ECHO</acronym>
  <official_title>Psychobiological Assessment and Enhancement of Team Cohesion and Psychological Resilience Using a Virtual Team Cohesion Test.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>San Francisco Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study attempts to identify the psychological, behavioral, physiological, and hormonal
      predictors and mechanisms of an individual's ability to develop cohesion in a group working
      together as a team; and examine if administration of the prosocial neuropeptide oxytocin
      enhances the development of team cohesion. Through a deeper understanding of the underlying
      psychobiological predictors and mechanisms of team cohesion, the prospective identification
      of individuals whose unique characteristics promote or inhibit the development of group
      cohesion will become possible.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will study three hundred and sixty subjects who will be randomized into
      teams of three. Teams will be randomized to receive oxytocin or placebo. The investigators
      will first measure baseline personality traits including prosocial orientation. Cohesion will
      then be measured using a cooperative, virtual unmanned aerial vehicle (UAV) flying mission.
      All online behavior will be recorded within the task and all offline, real world, behavior
      will be video recorded throughout the study by digital cameras for later behavioral coding.
      To measure biobehavioral synchrony, autonomic physiology will be recorded and saliva samples
      will be taken throughout behavioral testing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in score on computer game task</measure>
    <time_frame>Baseline, 2 hours after drug/placebo administration</time_frame>
    <description>Subjects will work together in groups of 2-4 performing a computer-based task flying a virtual plane.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in salivary oxytocin level</measure>
    <time_frame>10 minutes before drug/placebo administration; 1 hour, 2 hours, and 3 hours after drug/placebo administration</time_frame>
    <description>Four saliva samples will be taken from subjects to measure changes in salivary oxytocin levels.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Unit Cohesion</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group will receive either 20IU or 40IU intranasal oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group will receive a saline nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>20 International Units Intranasal Oxytocin</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>Saline nasal spray</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-28

          -  Speak English

          -  Ability to use a nasal spray

        Exclusion Criteria:

          -  Positive urine pregnancy test

          -  History of psychiatric or neurologic disorder

          -  Use of illicit drugs in the past month

          -  History of moderate-severe alcohol use disorder as defined by DSM-V criteria

          -  Sensitivity to preservatives (in particular E 216, E 218 and chlorobutanol
             hemihydrate)

          -  Nasal obstruction, discharge, or bleeding

          -  Habitually drinks large volumes of water

          -  Taking testosterone, estrogen/progesterone supplement, or serotonin-1a receptor
             agonists/antagonists

          -  Currently meets Diagnostic and Statistical Manual-5 (DSM-V) criteria for severe major
             depressive disorder with suicidal thoughts or actions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>28 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josh D Woolley, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California San Francisco, San Francisco Veterans Affairs Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LISA LIN, BA</last_name>
    <phone>415-221-4810</phone>
    <phone_ext>23318</phone_ext>
    <email>LISA.LIN@UCSF.EDU</email>
  </overall_contact>
  <location>
    <facility>
      <name>San Francisco VA Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LISA LIN, BA</last_name>
      <phone>415-221-4810</phone>
      <phone_ext>23318</phone_ext>
      <email>LISA.LIN@UCSF.EDU</email>
    </contact>
    <investigator>
      <last_name>Joshua Woolley, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2014</study_first_submitted>
  <study_first_submitted_qc>November 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2014</study_first_posted>
  <last_update_submitted>May 18, 2017</last_update_submitted>
  <last_update_submitted_qc>May 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Joshua Woolley</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cohesion</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>ROTC</keyword>
  <keyword>Virtual-reality</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

